The guide RNA determines where Cas9 acts by pairing with a complementary DNA sequence. Cas9 then cuts that selected location, linking sequence recognition to a physical break in the genome. This division of labor gives the method its adaptability: changing the guide RNA can redirect the editing system toward a different gene or genomic target for functional studies.
Gene disruption depends on what happens after the cut. Error-prone repair, often through nonhomologous end joining, can insert or delete DNA bases at the break. If these indels shift the gene’s reading frame, the resulting sequence can prevent normal gene expression. Thus, the knockout outcome is tied not only to targeting, but also to repair.
The double-strand break creates the critical opportunity for gene disruption because repair can alter the original DNA sequence. In CRISPR/Cas9 gene knockout, error-prone nonhomologous end joining may generate insertions or deletions rather than restoring the sequence exactly. Those changes can produce a frameshift, connecting the molecular repair event to loss of gene expression and observable biological effects.
A basic workflow begins by selecting a gene of interest and using a guide RNA designed to recognize a complementary DNA sequence. Cas9 is directed to that site and creates a double-strand break. The cell’s repair process can introduce disruptive insertions or deletions, after which researchers study how loss of the gene affects the cell, organism, or biological pathway.
Researchers use this approach when they need to connect a gene with its biological function or examine the consequences of losing its activity. It can support studies of inherited diseases, biological pathways, and drug-target validation. Because the target can be selected through the guide RNA, the method can be adapted to many functional genomics investigations.
In genetics, gene knockout can help model inherited diseases by examining the effects associated with disruption of a relevant gene. It also allows researchers to test whether a gene is a plausible drug target by studying the consequences of its loss. These findings contribute to broader functional genomics and may inform potential therapeutic strategies.